These findings show that targeting the increased expression of BCL-2 in CLL cells, together with blocking TrxR at the same time using a single gold cluster, is a hopeful approach for treating CLL cells [233]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.